Unternehmerreisen Fact-Finding Mission to Chongqing, Dalian/Liaoyang & Beijing 24 jun 2024–28 jun 2024 China
Fact-Finding Mission Fact-Finding Mission to Chongqing, Dalian/Liaoyang & Beijing 24 jun 2024–28 jun 2024 China
Voyages pour PME Fact-Finding Mission to Chongqing, Dalian/Liaoyang & Beijing 24 jun 2024–28 jun 2024 China
News 13 mar 2024 PSI developing new cancer therapy Researchers from the Paul Scherrer Institute (PSI) have developed a radiopharmaceutical to combat metastatic neuroendocrine tumors. After having ...
News 14 fev 2024 University of Fribourg discovers drug to combat age-related neuroinflammation Scientists at the University of Fribourg have uncovered a groundbreaking mechanism that could significantly mitigate age-related neuroinflammatio...
Actualités 12 jan 2022 ObsEva obtient des résultats positifs dans le traitement de l’endométriose Spécialisée dans la santé des femmes, la société biopharmaceutique genevoise ObsEva a annoncé des résultats préliminaires positifs de l'essai de ...
Aktuell 10 out 2023 MSD bekennt sich zum Standort Luzern MSD Schweiz will von Luzern aus weiter wachsen. Seit seiner Gründung vor 60 Jahren hat das Pharmaunternehmen kantonsweit eine halbe Milliarde Fr...
News 12 jan 2022 ObsEva achieves positive results in the treatment of endometriosis Geneva-based women’s health biopharmaceutical company ObsEva has announced positive topline results from the Phase 3 EDELWEISS 3 trial of linzago...
News 10 mai 2024 BioVersys extends Series C financing round to 44.9 million Swiss francs BioVersys is bolstering its partnership with GSK in order to accelerate the development of alpibectir for the treatment of tuberculosis. GSK is s...